Nordion: Resumption in Isotope Supply and New Sources Boost Prospects

A New York presenter recommends Nordion (NYSE: NDE, $11.64) as a buy. This provider of medical isotopes, targeted therapies, and sterilization technologies has seen its share of the isotope market fall drastically, due to interruptions in supply from the NRU reactor in Canada. In August, the reactor resumed operation after a prolonged shutdown. NDZ has also reached an agreement with a Russian-based producer to diversify its sources. Sales in the company's two other segments have been expanding at a rapid pace. Nordion has just announced a $0.40 dividend and a very sizable stock buyback. Resolution of the arbitration with the Canadian government expected in 2H 2011 can be a significant catalyst.